Anti-CD45RB antibodies
US7265212B2 · kind B2 · utility
15Cited by
4References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2002 |
| Grant date | Sep 4, 2007 |
| Priority date | — |
| Expiry date | Jan 17, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies which specifically recognize the human CD45 isoform RB are presented. These antibodies may be used to block undesirable immune reactions in patients with transplant rejection and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and autoimmune diabetes. Preferred antibodies are fully human, monoclonal antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.